EUVIMEDEUVIMED entdecken
Crossref

Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC

Gozde Mutevelizade, Nazim Aydin, Atike Pinar Erdoğan, Bilal Cagri Bozdemir, Nagihan Kolkıran, Elvan S.bilgin

Molecular Oncologic Imaging · 2025

DOI: 10.71286/moi.1727407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncologic Imaging, 2025. Verfasst von Gozde Mutevelizade und 5 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to assess the prognostic significance of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer (NSCLC) receiving nivolumab as second-line therapy. The study also explored associations between these parameters, treatment response, and survival outcomes.

Methods

A retrospective analysis was performed on 32 stage IV NSCLC patients who received at least four doses of nivolumab and underwent both baseline and follow-up PET/CT scans. Metabolic parameters, including SUVmax, SUVmean, total metabolic tumor volume (tMTV), and total lesion glycolysis (tTLG), were measured. Treatment response was classified according to EORTC criteria. Kaplan–Meier analysis and log-rank tests were applied for survival comparisons, and non-parametric methods evaluate associations.

Results

Patients with partial metabolic response demonstrated significantly longer post-nivolumab survival. Post-treatment SUVmax, SUVmean, and tTLG differed significantly among response categories. Pretreatment tMTV and tTLG, and post-treatment SUVmax, SUVmean, and tTLG, were significantly associated with mortality (p

Zitieren

APA

Mutevelizade, G., Aydin, N., Erdoğan, A. P., Bozdemir, B. C., Kolkıran, N., & S.bilgin, E. (2025). Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC. Molecular Oncologic Imaging. https://doi.org/10.71286/moi.1727407

Vancouver

Mutevelizade G, Aydin N, Erdoğan AP, Bozdemir BC, Kolkıran N, S.bilgin E. Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC. Molecular Oncologic Imaging. 2025. doi:10.71286/moi.1727407

BibTeX
@article{Mutevelizade2025,
  author = {Mutevelizade, Gozde and Aydin, Nazim and Erdoğan, Atike Pinar and Bozdemir, Bilal Cagri and Kolkıran, Nagihan and S.bilgin, Elvan},
  title = {Prognostic Value of PET-Based Metabolic Markers in Nivolumab-Treated NSCLC},
  journal = {Molecular Oncologic Imaging},
  year = {2025},
  doi = {10.71286/moi.1727407}
}
Kostenlos starten →